合成大麻素的使用与神经性恶性综合征之间关系的概念化。

IF 5 2区 医学 Q1 CLINICAL NEUROLOGY
Vincent Zhang, Alexis June Wirtz, Anmol Dhingra, Ashar Zahid, Najeeb Hussain
{"title":"合成大麻素的使用与神经性恶性综合征之间关系的概念化。","authors":"Vincent Zhang,&nbsp;Alexis June Wirtz,&nbsp;Anmol Dhingra,&nbsp;Ashar Zahid,&nbsp;Najeeb Hussain","doi":"10.1111/bdi.13503","DOIUrl":null,"url":null,"abstract":"<p>The patient is a 29-year-old female with history of bipolar disorder (multiple past psychiatric admissions) and cannabis/synthetic cannabinoid (SC) use disorder who was recently admitted to an inpatient psychiatric facility for disorganization and agitation. Following this hospitalization, she was discharged on aripiprazole 20 mg daily and lithium 300 mg twice daily. Four days later, she presented to the emergency room following multiple seizure-like episodes and aggressive behavior. Due to ongoing agitation with violence, patient required multiple doses of droperidol, midazolam, hydroxyzine, and was status post administration of soft restraints. The patient's mother described and recorded three episodes of diffuse jerking that lasted 5 min each, with urinary incontinence and oral frothing. Each episode self-resolved, and the patient was conversant throughout episodes with no post-ictal state nor tongue-biting. Neurology was consulted and concluded that her presentation was not consistent with seizures. The patient subsequently was found to have bradykinesia, rigidity, and a rapid increase in creatine kinase from 310 on arrival to a level of 2428 during evaluation- mild neuroleptic malignant syndrome (NMS) was suspected. Her symptoms were thought to be due to use of aripiprazole and droperidol, leading to NMS; however, toxicity from SC's could not be ruled out. Indeed, this was actually suspected, given that the patient had previously been admitted multiple times with similar medication regimens (with higher doses of antipsychotics) without developing NMS. Antipsychotics were discontinued, restraints were avoided as much as possible, and benzodiazepines were instead started for agitation. This resulted in eventual resolution of both her psychiatric and physical symptoms following a short stay in the inpatient unit.</p><p>Neuroleptic Malignant Syndrome (NMS) is a well-known side effect of potentially all antipsychotics, as antagonism of dopamine receptors lead to drops in neurotransmitter activity within dopaminergic pathways.<span><sup>1</sup></span> It has a textbook triad of fever, muscle rigidity, and altered mental status (AMS), but in clinical practice, the majority of cases actually present heterogeneously.<span><sup>2</sup></span> Similarly, synthetic cannabinoids (SC) possess a widely varying drug profile, due to the vast number of derivatives sold. In recent years, SC have become increasingly popular due to their lower cost, easy obtainability and non-detectability on traditional drug screens.<span><sup>3</sup></span> This is of increasing concern, due to their vastly more unpredictable, severe side-effects compared to cannabis- zero fatalities have been seen with cannabis toxicity, while many have been reported due to SC. Psychiatrically, SC has been show to drastically exacerbate certain conditions including schizophrenia, anxiety, and bipolar disorder. For psychosis in particular, it has been shown that SC use serves as an agonist at cannabinoid type-1 receptors in the brain, leading to acute increases in dopamine.<span><sup>4</sup></span></p><p>NMS and SC use can present very similarly, including increases in CPK, agitation, rigidity, altered mental status, fever etc.<span><sup>1, 4</sup></span> For our patient, both likely played a role but which contributed more? It is impossible to tell- the former is a clinical diagnosis while SC toxicity cannot be definitively measured.<span><sup>4</sup></span> Regardless, generalizable takeaways can be made. All patients who require antipsychotics (for bipolar disorder, psychosis etc.) should be screened for concurrent SC use. SC use can precipitate muscle injury, leading to elevations in CPK and consequently rhabdomyolysis. We posit this may lead to lowering the threshold for developing NMS following antipsychotic usage, but even if it does not, combining both will almost certainly lead to worse muscle injury.<span><sup>5</sup></span> Instead, benzodiazepines and non-dopamine acting drugs should be used unless otherwise necessary. Furthermore, for patients who use synthetic cannabinoids, physical restraints should be minimized, as immobilization drastically increases risk of muscle injury. Both of these points are currently not well-emphasized in the existing literature, but our experience managing patients who present with SC use in an urban, inner-city hospital points towards this being especially important. Many of our patients who present following SC use have acute psychiatric symptoms (aggression, agitation, altered mental status etc.) that require sedation for both their own safety and that of our staff. Choosing the correct form of management is key to reducing their length of stay and morbidity/mortality. We believe that the increasing ubiquity of synthetic cannabinoids, combined with their potential for adverse reactions with existing medications, highlights the need for further molecular research in this area.</p><p>All authors declare that they have no conflicts of interest.</p><p>Informed consent was obtained from the patient, and identifiers were anonymized. Ethics approval from our ethics committee was waived due to the manuscript being a case report.</p>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 2","pages":"161-162"},"PeriodicalIF":5.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13503","citationCount":"0","resultStr":"{\"title\":\"Conceptualizing the relationship between synthetic cannabinoid use and neuroleptic malignant syndrome\",\"authors\":\"Vincent Zhang,&nbsp;Alexis June Wirtz,&nbsp;Anmol Dhingra,&nbsp;Ashar Zahid,&nbsp;Najeeb Hussain\",\"doi\":\"10.1111/bdi.13503\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The patient is a 29-year-old female with history of bipolar disorder (multiple past psychiatric admissions) and cannabis/synthetic cannabinoid (SC) use disorder who was recently admitted to an inpatient psychiatric facility for disorganization and agitation. Following this hospitalization, she was discharged on aripiprazole 20 mg daily and lithium 300 mg twice daily. Four days later, she presented to the emergency room following multiple seizure-like episodes and aggressive behavior. Due to ongoing agitation with violence, patient required multiple doses of droperidol, midazolam, hydroxyzine, and was status post administration of soft restraints. The patient's mother described and recorded three episodes of diffuse jerking that lasted 5 min each, with urinary incontinence and oral frothing. Each episode self-resolved, and the patient was conversant throughout episodes with no post-ictal state nor tongue-biting. Neurology was consulted and concluded that her presentation was not consistent with seizures. The patient subsequently was found to have bradykinesia, rigidity, and a rapid increase in creatine kinase from 310 on arrival to a level of 2428 during evaluation- mild neuroleptic malignant syndrome (NMS) was suspected. Her symptoms were thought to be due to use of aripiprazole and droperidol, leading to NMS; however, toxicity from SC's could not be ruled out. Indeed, this was actually suspected, given that the patient had previously been admitted multiple times with similar medication regimens (with higher doses of antipsychotics) without developing NMS. Antipsychotics were discontinued, restraints were avoided as much as possible, and benzodiazepines were instead started for agitation. This resulted in eventual resolution of both her psychiatric and physical symptoms following a short stay in the inpatient unit.</p><p>Neuroleptic Malignant Syndrome (NMS) is a well-known side effect of potentially all antipsychotics, as antagonism of dopamine receptors lead to drops in neurotransmitter activity within dopaminergic pathways.<span><sup>1</sup></span> It has a textbook triad of fever, muscle rigidity, and altered mental status (AMS), but in clinical practice, the majority of cases actually present heterogeneously.<span><sup>2</sup></span> Similarly, synthetic cannabinoids (SC) possess a widely varying drug profile, due to the vast number of derivatives sold. In recent years, SC have become increasingly popular due to their lower cost, easy obtainability and non-detectability on traditional drug screens.<span><sup>3</sup></span> This is of increasing concern, due to their vastly more unpredictable, severe side-effects compared to cannabis- zero fatalities have been seen with cannabis toxicity, while many have been reported due to SC. Psychiatrically, SC has been show to drastically exacerbate certain conditions including schizophrenia, anxiety, and bipolar disorder. For psychosis in particular, it has been shown that SC use serves as an agonist at cannabinoid type-1 receptors in the brain, leading to acute increases in dopamine.<span><sup>4</sup></span></p><p>NMS and SC use can present very similarly, including increases in CPK, agitation, rigidity, altered mental status, fever etc.<span><sup>1, 4</sup></span> For our patient, both likely played a role but which contributed more? It is impossible to tell- the former is a clinical diagnosis while SC toxicity cannot be definitively measured.<span><sup>4</sup></span> Regardless, generalizable takeaways can be made. All patients who require antipsychotics (for bipolar disorder, psychosis etc.) should be screened for concurrent SC use. SC use can precipitate muscle injury, leading to elevations in CPK and consequently rhabdomyolysis. We posit this may lead to lowering the threshold for developing NMS following antipsychotic usage, but even if it does not, combining both will almost certainly lead to worse muscle injury.<span><sup>5</sup></span> Instead, benzodiazepines and non-dopamine acting drugs should be used unless otherwise necessary. Furthermore, for patients who use synthetic cannabinoids, physical restraints should be minimized, as immobilization drastically increases risk of muscle injury. Both of these points are currently not well-emphasized in the existing literature, but our experience managing patients who present with SC use in an urban, inner-city hospital points towards this being especially important. Many of our patients who present following SC use have acute psychiatric symptoms (aggression, agitation, altered mental status etc.) that require sedation for both their own safety and that of our staff. Choosing the correct form of management is key to reducing their length of stay and morbidity/mortality. We believe that the increasing ubiquity of synthetic cannabinoids, combined with their potential for adverse reactions with existing medications, highlights the need for further molecular research in this area.</p><p>All authors declare that they have no conflicts of interest.</p><p>Informed consent was obtained from the patient, and identifiers were anonymized. Ethics approval from our ethics committee was waived due to the manuscript being a case report.</p>\",\"PeriodicalId\":8959,\"journal\":{\"name\":\"Bipolar Disorders\",\"volume\":\"27 2\",\"pages\":\"161-162\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13503\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bipolar Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bdi.13503\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bipolar Disorders","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bdi.13503","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

患者是一名29岁女性,有双相情感障碍史(过去多次精神科住院)和大麻/合成大麻素(SC)使用障碍,最近因精神紊乱和躁动而住进精神病院。住院后,她出院时服用阿立哌唑每日20毫克,锂300毫克,每日两次。四天后,她因多次癫痫发作和攻击性行为而被送往急诊室。由于持续的躁动和暴力,患者需要多剂量的哌啶醇、咪达唑仑、羟嗪,并在给予软约束后处于状态。患者的母亲描述并记录了三次弥漫性抽搐,每次持续5分钟,伴有尿失禁和口腔泡沫。每次发作自行消退,患者在整个发作过程中都很熟悉,没有发作后状态,也没有咬舌头。我们咨询了神经病学,结论是她的表现与癫痫发作不一致。随后发现患者运动迟缓,僵硬,肌酸激酶从到达时的310迅速增加到评估时的2428水平-怀疑轻度抗精神病药恶性综合征(NMS)。她的症状被认为是由于使用阿立哌唑和氟哌啶醇,导致NMS;然而,SC的毒性也不能排除。事实上,考虑到患者之前多次接受类似的药物治疗(使用更高剂量的抗精神病药物)而没有发生NMS,这实际上是怀疑的。停用抗精神病药物,尽可能避免约束,转而使用苯二氮卓类药物治疗躁动。这导致在住院病房短暂停留后,她的精神和身体症状最终得到解决。抗精神病药恶性综合征(NMS)是一种众所周知的副作用,可能是所有抗精神病药的副作用,因为多巴胺受体的拮抗作用导致多巴胺能通路内神经递质活性下降它具有典型的发烧、肌肉僵硬和精神状态改变(AMS)三联征,但在临床实践中,大多数病例实际上是异质性的同样,由于大量的衍生物出售,合成大麻素(SC)具有广泛不同的药物特征。近年来,SC因其成本较低,易于获得,在传统药物筛选中无法检测到而越来越受欢迎这一点越来越令人担忧,因为与大麻相比,它们的副作用更不可预测,更严重——大麻毒性没有造成任何死亡,而有许多人因SC而死亡。精神病学上,SC已被证明会严重加剧某些疾病,包括精神分裂症、焦虑症和双相情感障碍。特别是对于精神病,研究表明,SC的使用可以作为大脑中大麻素1型受体的激动剂,导致多巴胺的急性增加。nms和SC的使用表现非常相似,包括CPK增加、躁动、僵硬、精神状态改变、发烧等。对于我们的患者来说,两者都可能起作用,但哪一个贡献更大?这是不可能告诉-前者是临床诊断,而SC毒性不能明确测量无论如何,可以得出一些概括的结论。所有需要抗精神病药物(双相情感障碍、精神病等)的患者都应筛查是否同时使用SC。SC的使用会导致肌肉损伤,导致CPK升高,从而导致横纹肌溶解。我们认为这可能会降低抗精神病药物使用后发生NMS的门槛,但即使没有,两者结合也几乎肯定会导致更严重的肌肉损伤除非有必要,否则应使用苯二氮卓类药物和非多巴胺作用药物。此外,对于使用合成大麻素的患者,应尽量减少身体限制,因为固定会大大增加肌肉损伤的风险。这两点目前在现有文献中都没有得到很好的强调,但我们管理在城市、市中心医院使用SC的患者的经验表明,这一点尤其重要。我们的许多患者在使用SC后出现急性精神症状(攻击性、躁动、精神状态改变等),为了他们自己和我们工作人员的安全,需要镇静。选择正确的治疗方式是减少住院时间和发病率/死亡率的关键。我们认为,合成大麻素的日益普及,加上它们与现有药物的潜在不良反应,突出了在这一领域进行进一步分子研究的必要性。所有作者声明他们没有利益冲突。获得患者的知情同意,标识符匿名化。 由于稿件是病例报告,我们的伦理委员会放弃了伦理审批。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Conceptualizing the relationship between synthetic cannabinoid use and neuroleptic malignant syndrome

The patient is a 29-year-old female with history of bipolar disorder (multiple past psychiatric admissions) and cannabis/synthetic cannabinoid (SC) use disorder who was recently admitted to an inpatient psychiatric facility for disorganization and agitation. Following this hospitalization, she was discharged on aripiprazole 20 mg daily and lithium 300 mg twice daily. Four days later, she presented to the emergency room following multiple seizure-like episodes and aggressive behavior. Due to ongoing agitation with violence, patient required multiple doses of droperidol, midazolam, hydroxyzine, and was status post administration of soft restraints. The patient's mother described and recorded three episodes of diffuse jerking that lasted 5 min each, with urinary incontinence and oral frothing. Each episode self-resolved, and the patient was conversant throughout episodes with no post-ictal state nor tongue-biting. Neurology was consulted and concluded that her presentation was not consistent with seizures. The patient subsequently was found to have bradykinesia, rigidity, and a rapid increase in creatine kinase from 310 on arrival to a level of 2428 during evaluation- mild neuroleptic malignant syndrome (NMS) was suspected. Her symptoms were thought to be due to use of aripiprazole and droperidol, leading to NMS; however, toxicity from SC's could not be ruled out. Indeed, this was actually suspected, given that the patient had previously been admitted multiple times with similar medication regimens (with higher doses of antipsychotics) without developing NMS. Antipsychotics were discontinued, restraints were avoided as much as possible, and benzodiazepines were instead started for agitation. This resulted in eventual resolution of both her psychiatric and physical symptoms following a short stay in the inpatient unit.

Neuroleptic Malignant Syndrome (NMS) is a well-known side effect of potentially all antipsychotics, as antagonism of dopamine receptors lead to drops in neurotransmitter activity within dopaminergic pathways.1 It has a textbook triad of fever, muscle rigidity, and altered mental status (AMS), but in clinical practice, the majority of cases actually present heterogeneously.2 Similarly, synthetic cannabinoids (SC) possess a widely varying drug profile, due to the vast number of derivatives sold. In recent years, SC have become increasingly popular due to their lower cost, easy obtainability and non-detectability on traditional drug screens.3 This is of increasing concern, due to their vastly more unpredictable, severe side-effects compared to cannabis- zero fatalities have been seen with cannabis toxicity, while many have been reported due to SC. Psychiatrically, SC has been show to drastically exacerbate certain conditions including schizophrenia, anxiety, and bipolar disorder. For psychosis in particular, it has been shown that SC use serves as an agonist at cannabinoid type-1 receptors in the brain, leading to acute increases in dopamine.4

NMS and SC use can present very similarly, including increases in CPK, agitation, rigidity, altered mental status, fever etc.1, 4 For our patient, both likely played a role but which contributed more? It is impossible to tell- the former is a clinical diagnosis while SC toxicity cannot be definitively measured.4 Regardless, generalizable takeaways can be made. All patients who require antipsychotics (for bipolar disorder, psychosis etc.) should be screened for concurrent SC use. SC use can precipitate muscle injury, leading to elevations in CPK and consequently rhabdomyolysis. We posit this may lead to lowering the threshold for developing NMS following antipsychotic usage, but even if it does not, combining both will almost certainly lead to worse muscle injury.5 Instead, benzodiazepines and non-dopamine acting drugs should be used unless otherwise necessary. Furthermore, for patients who use synthetic cannabinoids, physical restraints should be minimized, as immobilization drastically increases risk of muscle injury. Both of these points are currently not well-emphasized in the existing literature, but our experience managing patients who present with SC use in an urban, inner-city hospital points towards this being especially important. Many of our patients who present following SC use have acute psychiatric symptoms (aggression, agitation, altered mental status etc.) that require sedation for both their own safety and that of our staff. Choosing the correct form of management is key to reducing their length of stay and morbidity/mortality. We believe that the increasing ubiquity of synthetic cannabinoids, combined with their potential for adverse reactions with existing medications, highlights the need for further molecular research in this area.

All authors declare that they have no conflicts of interest.

Informed consent was obtained from the patient, and identifiers were anonymized. Ethics approval from our ethics committee was waived due to the manuscript being a case report.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bipolar Disorders
Bipolar Disorders 医学-精神病学
CiteScore
8.20
自引率
7.40%
发文量
90
审稿时长
6-12 weeks
期刊介绍: Bipolar Disorders is an international journal that publishes all research of relevance for the basic mechanisms, clinical aspects, or treatment of bipolar disorders and related illnesses. It intends to provide a single international outlet for new research in this area and covers research in the following areas: biochemistry physiology neuropsychopharmacology neuroanatomy neuropathology genetics brain imaging epidemiology phenomenology clinical aspects and therapeutics of bipolar disorders Bipolar Disorders also contains papers that form the development of new therapeutic strategies for these disorders as well as papers on the topics of schizoaffective disorders, and depressive disorders as these can be cyclic disorders with areas of overlap with bipolar disorders. The journal will consider for publication submissions within the domain of: Perspectives, Research Articles, Correspondence, Clinical Corner, and Reflections. Within these there are a number of types of articles: invited editorials, debates, review articles, original articles, commentaries, letters to the editors, clinical conundrums, clinical curiosities, clinical care, and musings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信